Security key
696389402
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 260,593
- Total 13F value
- $176,598
- Share change
- +61,370
- SEC-reported price per share
- $0.68
- Number of holders
- 11
- Value change
- -$26,884
- Number of buys
- 8
- Number of sells
- 2
- Shares outstanding
- 173,946,000
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
11
Top holders
10
PALI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
PALISADE BIO, INC. SEC filings
PALISADE BIO, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 696389402
Recent filing periods:
Ownership snapshot
Top reported holders of PALI - PALISADE BIO, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Yuma Regional Medical Center
Comparable rows
10/15
Latest evidence
31 Mar 2025
13D/G
13F
3/4/5
Lead comparable stake: 10%
5 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
10%
Cetera Investment Advisers
0.04%
Marex Group Ltd
0.02%
GEODE CAPITAL MANAGEMENT, LLC
0.01%
UBS Group AG
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
|
$335,053
471,906 shares
|
+$132,407 | 31 Mar 2025 |
| Cetera Investment Advisers |
13F
Company
|
0.04%
|
$115,510
70,006 shares
|
— | 31 Dec 2024 |
| Marex Group Ltd |
13F
Company
|
0.02%
|
$59,002
35,759 shares
|
— | 31 Dec 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.01%
|
$16,585
10,052 shares
|
— | 31 Dec 2024 |
| UBS Group AG |
13F
Company
|
0.01%
|
$14,807
8,974 shares
|
— | 31 Dec 2024 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
0%
|
$7,732
4,686 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
260,593
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2026 Across Filers
Q1 2026 holders
95
Q1 2025 holders
11
Holder diff
-84
| Investor | Q1 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend